AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

# LISTING OF CLAIMS:

1. (currently amended): A compound represented by the following formula (I):

wherein R<sup>1</sup> represents hydrogen;

R<sup>2</sup> represents hydrogen, alkyl, amino, cyano, halogen, halogenoalkenyl, carboxyl, alkoxycarbonyl, carbamoyl, *N*,*N*-dialkylcarbamoyl, *N*-hydroxyalkylcarbamoyl, aryl selected from the group consisting of phenyl, naphthyl, anthryl, phenanthryl and biphenylyl, which may havehas a substituent, or a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxycarbonyl, carboxyalkoxy, alkoxycarbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl, *N*,*N*-dialkylaminoalkylcarbonyl, carboxyalkyl, alkoxycarbonylalkoxy, morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, *N*-alkylaminosulfonylalkyl, *N*,*N*-dialkylaminosulfonylalkyl, aralkyl, alkylsulfonylamino, *N*-alkylaminosulfonylamino, *N*,*N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino, *N*,*N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino,

a group represented by the following formula (II):

$$-A^{1}-Y^{1}$$
 (II)

wherein  $A^1$  represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and  $Y^1$  represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y<sup>1</sup> is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, N-alkylamino, N,N-dialkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkyl-N-alkoxycarbonylamino and N-alkyl-N-alkoxycarbonylaminoalkyl,

a group represented by the following formula (III)

$$-A^2$$
-(C=O)-Y<sup>2</sup> (III)

wherein A<sup>2</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y<sup>2</sup> represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on  $Y^2$  represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, N-alkylamino, N-dialkylamino, N-alkylaminoalkyl, N-dialkylaminoalkyl, N-alkyl-N-alkoxycarbonylamino and N-alkyl-N-alkoxycarbonylaminoalkyl,

a group represented by the following formula (IV)

$$-A^3-N(R^4)(R^5)$$
 (IV)

wherein A<sup>3</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-(C=O)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group; and R<sup>4</sup> and R<sup>5</sup> each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, or alkyldiphenylsilyloxyalkyl, and

a group represented by the following formula (V)

$$-A^4$$
-(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>) (V)

wherein A<sup>4</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

R<sup>6</sup> and R<sup>7</sup> each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*,*N*-dialkylaminoalkylcarbonyl, or alkyldiphenylsilyloxyalkyl;

R<sup>3</sup> represents hydrogen;

Ar represents phenylene, which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond; and

G represents halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxycarbonyl, *N*-alkylamino, *N*,*N*-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, pyrrolidinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

heterocyclic group which may have a substituent selected from the group consisting of indolyl, indolinyl, isoindolyl, isoindolinyl, indazolyl, quinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, 4H-quinolizinyl, quinazolinyl, dihydroquinazolinyl, tetrahydroguinazolinyl, cinnolinyl, tetrahydrocinnolinyl, indolizinyl, tetrahydroindolizinyl, benzothiazolyl, tetrahydrobenzothiazolyl, benzoxazolyl, benzoisothiazolyl, benzoisooxazolyl, benzoimidazolyl, naphthyridinyl, tetrahydronaphthyridinyl, thienopyridyl, tetrahydrothienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, thiazolopyridazinyl, tetrahydrothiazolopyridazinyl, pyrrolopyridyl, dihydropyrrolopyridyl, tetrahydropyrrolopyridyl, pyrrolopyrimidinyl, dihydropyrrolopyrimidinyl, pyridopyrimidinyl, tetrahydropyridopyrimidinyl, pyranothiazolyl, dihydropyranothiazolyl, furopyridyl, tetrahydrofuropyridyl, oxazolopyridyl, tetrahydrooxazolopyridyl, oxazolopyridazinyl, tetrahydrooxazolopyridazinyl, pyrrolothiazolyl, dihydropyrrolothiazolyl, pyrrolooxazolyl, dihydropyrrolooxazolyl, thienopyrrolyl, thiazolopyrimidinyl, thiazolooxazolyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, tetrahydroimidazopyridyl, pyrazinopyridazinyl, imidazotriazinyl, oxazolopyridyl, benzooxepinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl, benzotriazepinyl, thienoazepinyl, tetrahydrothienoazepinyl, thienodiazepinyl, thienotriazepinyl, thiazoloazepinyl, and tetrahydrothiazoloazepinyl, which may have a substituent, wherein the substituent represents one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (C):

Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, *N*-alkylamino, *N*,*N*-dialkylamino, *N*-alkylaminoalkyl, *N*,*N*-dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto,

Application No.: 10/551,414

alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof.

2-5. (canceled).

6. (currently amended): The compound represented by formula (I) according to claim 1 wherein G is halogen, halogenoalkenyl, alkoxy, alkoxycarbonyl, *N*,*N*-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a salt thereof.

7. (withdrawn): The compound represented by formula (I) according to claim 1, wherein any one of  $\mathbb{R}^2$ ,  $\mathbb{R}^3$ , Ar and G is labeled with a radiation-releasing isotope, or a salt thereof.

**8.** (withdrawn): The compound represented by formula (I) according to claim 7, wherein the radiation-releasing isotope is a radioactive iodine atom, or a salt thereof.

9. (canceled).

Application No.: 10/551,414

10. (previously presented): A pharmaceutical composition which comprises the compound represented by formula (I) according to claim 1, or a salt thereof, and a pharmaceutically acceptable carrier.

#### 11-13. (canceled).

- 14. (previously presented): An agent for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises the compound represented by formula (I) according to claim 1, or a salt thereof.
- 15. (withdrawn): A radioactive diagnosing agent, which comprises the compound represented by formula (I) according to claim 7, or a salt thereof.

#### 16-17. (canceled).

- 18. (withdrawn): A method for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises administering the compound represented by formula (I) according to claim 1, or a salt thereof.
- 19. (withdrawn): A method for diagnosing accumulation of amyloid, which comprises administering the compound represented by formula (I) according to claim 7, or a salt thereof; and detecting a radiation-releasing isotope.

Application No.: 10/551,414

Claims 20-23 (canceled).

24. (currently amended): The compound of claim 1 according to formula (I), wherein G represents a saturated or unsaturated 5- to 7- membered heterocyclic group which may have a substituent selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl and triazinyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from Group (C), or a salt thereof.

### 25. -26 (canceled):

- 27. (currently amended): The compound of formula (I) according to claim 1, wherein G represents a fluorine atom, an iodine atom, 2-fluoroethyl, 3-fluoropropyl, methoxy[[,]]; or oxazolyl, pyridyl, oxadiazolyl, imidazopyridyl, imidazothiazolyl-andor benzothiazolyl, which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from Group (C), or salt thereof.
- **28.** (withdrawn-currently amended): A method for treating Creutzfeldt-Jacob disease or Gerstmann Straussler Scheinker syndrome, which comprises administering a compound represented by formula (I):

$$\begin{array}{c|c}
R^1 & R^3 \\
\hline
N-N-Ar-X-G
\end{array} (I)$$

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

wherein

R<sup>1</sup> represents hydrogen;

R<sup>2</sup> represents hydrogen, alkyl, amino, cyano, halogen, halogenoalkenyl, carboxyl, alkoxycarbonyl, carbamoyl, *N*,*N*-dialkylcarbamoyl, *N*-hydroxyalkylcarbamoyl, aryl selected from the group consisting of phenyl, naphthyl, anthryl, phenanthryl and biphenylyl, which may have has a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolidinyl, piperazinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein the substituent is one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (A):

Group (A):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, cyano, nitro, hydroxyalkyl, carboxyl, alkoxycarbonyl, carboxyalkoxy, alkoxycarbonylalkoxy, aralkyloxy, *N*-alkylaminoalkylcarbonyl, *N*,*N*-dialkylaminoalkylcarbonyl, carboxyalkyl, alkoxycarbonylalkoxy, morpholinocarbonylalkoxy, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*-alkylaminosulfonyl, sulfo, alkylsulfonyl, alkylsulfonylalkyl, tetrazolyl, trialkyltin, trialkylsilyl, aminosulfonylalkyl, *N*-alkylaminosulfonylalkyl, *N*,*N*-dialkylaminosulfonylalkyl, aralkyl, alkylsulfonylamino, *N*-alkylaminosulfonylamino, *N*,*N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino, *N*,*N*-dialkylaminosulfonylamino, *N*-alkylaminoacylamino, *N*,*N*-dialkylaminoacylamino, *N*,*N*-dialkylaminoacylamino,

AMENDMENT UNDER 37 C.F.R. § 1.114(c) Application No.: 10/551,414

a group represented by the following formula (II):

$$-A^{1}-Y^{1}$$
 (II)

wherein A<sup>1</sup> represents a single bond or linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl; and Y<sup>1</sup> represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y<sup>1</sup> is one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, N-alkylamino, N,N-dialkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkyl-N-alkoxycarbonylamino and N-alkyl-N-alkoxycarbonylaminoalkyl,

a group represented by the following formula (III)

$$-A^{2}-(C=O)-Y^{2}$$
 (III)

wherein A<sup>2</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and Y<sup>2</sup> represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent,

wherein the substituent on Y<sup>2</sup> represents one substituent or 2 or 3 substituents, which are the same or different, selected from the group consisting of halogen, alkyl, halogenoalkyl, carboxyl, alkoxycarbonyl, aminoalkyl, N-alkylamino, N,N-dialkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, N-alkyl-N-alkoxycarbonylamino and N-alkyl-N-alkoxycarbonylaminoalkyl,

a group represented by the following formula (IV)

$$-A^3-N(R^4)(R^5)$$
 (IV)

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

wherein A³ represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group, or linear, branched or cyclic-(C=O)-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the nitrogen atom in the group; and R⁴ and R⁵ each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*-alkylaminoalkylcarbonyl, *N*,*N*-dialkylaminoalkylcarbonyl or alkyldiphenylsilyloxyalkyl, and

a group represented by the following formula (V)

$$-A^4$$
-(C=O)-N(R<sup>6</sup>)(R<sup>7</sup>) (V)

wherein A<sup>4</sup> represents a single bond, linear, branched or cyclic alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, or linear, branched or cyclic-O-alkylene having from 1 to 6 carbon atoms which may be substituted with halogen or hydroxyl, in which the alkylene binds to the carbonyl in the group; and

R<sup>6</sup> and R<sup>7</sup> each independently represents hydrogen, alkyl, hydroxyalkyl, halogenoalkyl, acyl, alkoxycarbonyl, alkylsulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, *N*,*N*-dialkylaminoalkylcarbonyl, or alkyldiphenylsilyloxyalkyl;

R<sup>3</sup> represents hydrogen;

Ar represents phenylene, which may have one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (B):

Group (B):

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

Application No.: 10/551,414

halogen, hydroxyl group, alkyl, alkoxy, halogenoalkyl, cyano, amino, nitro, alkylamino, hydroxyalkyl, carboxyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, *N*-alkylaminosulfonyl, *N*,*N*-dialkylaminosulfonyl, sulfo, trialkyltin and trialkylsilyl;

X represents a single bond; and

G represents halogen, halogenoalkyl, halogenoalkenyl, halogenoalkynyl, alkoxy, alkoxycarbonyl, N-alkylamino, N,N-dialkylamino, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated bicyclic or tricyclic condensed hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group selected from the group consisting of furyl, thienyl, pyrazolyl, imidazolyl, pyrazolinyl, oxazolyl, isoxazolyl, oxazolinyl, thiazolyl, thiazolinyl, thiadiazolyl, furazanyl, pyranyl, pyridyl, tetrahydropyridyl, pyrimidinyl, pyrazinyl, piperazinyl, pyrrolidinyl, piperidinyl, oxazinyl, oxadiazinyl, morpholinyl, thiazinyl, thiadiazinyl, thiomorpholinyl, tetrazolyl, triazolyl, triazinyl, azepinyl, diazepinyl and triazepinyl, which may have a substituent, or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group selected from the group consisting of indolyl, indolinyl, isoindolyl, isoindolyl, indazolyl, guinolyl, dihydroquinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, 4Hquinolizinyl, quinazolinyl, dihydroquinazolinyl, tetrahydroquinazolinyl, cinnolinyl, tetrahydrocinnolinyl, indolizinyl, tetrahydroindolizinyl, benzothiazolyl, tetrahydrobenzothiazolyl, benzoxazolyl, benzoisothiazolyl, benzoisooxazolyl, benzoimidazolyl, naphthyridinyl, tetrahydronaphthyridinyl, thienopyridyl, tetrahydrothienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, thiazolopyridazinyl, tetrahydrothiazolopyridazinyl, pyrrolopyridyl, dihydropyrrolopyridyl, tetrahydropyrrolopyridyl, pyrrolopyrimidinyl, dihydropyrrolopyrimidinyl, pyridopyrimidinyl, tetrahydropyridopyrimidinyl, pyranothiazolyl,

Application No.: 10/551,414

dihydropyranothiazolyl, furopyridyl, tetrahydrofuropyridyl, oxazolopyridyl, tetrahydrooxazolopyridyl, pyrrolothiazolyl, dihydropyrrolothiazolyl, pyrrolooxazolyl, dihydropyrrolooxazolyl, thienopyrrolyl, thiazolopyrimidinyl, thiazolooxazolyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, pyrazinopyridazinyl, imidazotriazinyl, oxazolopyridyl, benzooxepinyl, benzoazepinyl, tetrahydrobenzoazepinyl, benzodiazepinyl, benzodiazepinyl, thienodiazepinyl, thienodiazepinyl, thienodiazepinyl, thienodiazepinyl, thienodiazepinyl, thienotriazepinyl, thiazoloazepinyl, and tetrahydrothiazoloazepinyl, which may have a substituent, wherein the substituent represents one substituent or 2 or 3 substituents, which are the same or different, selected from the following Group (C):

Group (C):

halogen, hydroxyl, alkyl, alkoxy, halogenoalkyl, halogenoalkenyl, halogenoalkoxy, cyano, amino, nitro, N-alkylamino, N,N-dialkylamino, N-alkylaminoalkyl, N,N-dialkylaminoalkyl, hydroxyalkyl, carboxyl, carboxyalkyl, alkoxycarbonyl, carbamoyl, mercapto, alkylthio, aminosulfonyl, N-alkylaminosulfonyl, N,N-dialkylaminosulfonyl, oxo, trialkyltin and trialkylsilyl,

or a salt thereof.

29. (new): The compound of formula (I) according to claim 27, wherein G represents oxazolyl, pyridyl, oxadiazolyl, imidazopyridyl, imidazothiazolyl or benzothiazolyl, which may have a substituent, wherein the sutstituent is one substituent or 2 or 3 substituents, which are the same or different, selected from Group (C), or a salt thereof.

Application No.: 10/551,414

- 30. (new): The compound of formula (I) according to claim 1 or a salt thereof, wherein G represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein said heterocyclic group is selected from furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, isoindolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl, tetrahydroisoquinolyl, benzothiazolyl, benzoxazolyl, benzoimidazolyl, thienopyridyl, thiazolopyridyl, tetrahydrothiazolopyridyl, pyrrolopyridyl, pyrrolopyrimidinyl, oxazolopyridyl, tetrahydrooxazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidazopyridyl, and tetrahydroimidazopyridyl, and wherein the substituent is one or 2 or 3 substituents, which are the same or different, selected from Group (C).
- 31. (new): The compound of formula (I) according to claim 1 or a salt thereof, wherein G represents a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent or a saturated or unsaturated bicyclic or tricyclic condensed heterocyclic group which may have a substituent, wherein said heterocyclic group is selected from furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, tetrahydroquinolyl, tetrahydrothiazolopyridyl, imidazothiazolyl, imidazooxazolyl, imidazopyrimidinyl, imidiazopyridyl and tetrahydroimidazopyridyl, and wherein the substituent is one or 2 or 3 substituents, which are the same or different, selected from Group (C).